沙库巴曲缬沙坦治疗射血分数保留心衰患者的表观难治性高血压
本文是PARAGON-HF试验的事后分析,评估沙库巴曲缬沙坦对HFpEF合并表观难治性高血压的疗效。共4795例患者按缬沙坦导入期末收缩压分类,其中731例(15.2%)有表观难治性高血压,135例(2.8%)有表观MRA难治性高血压。结果显示沙库巴曲缬沙坦较缬沙坦更显著降低收缩压,并提高血压控制达标比例。
要点
- HFpEF患者中表观难治性高血压并不少见,占15.2%。
- 表观难治性高血压患者主要终点事件率更高(17.3 vs 13.4/100人年)。
- 沙库巴曲缬沙坦较缬沙坦更有效降低表观难治性高血压患者的收缩压。
核心结论
- 沙库巴曲缬沙坦可能对HFpEF患者的表观难治性高血压有用。
- 即使在使用包括MRA在内的至少四类降压药后血压仍高的患者中也可能有效。
研究设计与样本
- PARAGON-HF试验的事后分析,比较沙库巴曲缬沙坦与缬沙坦。
- 根据缬沙坦导入期末收缩压对4795例患者进行分类。
- 表观难治性高血压定义为使用缬沙坦、钙通道阻滞剂和利尿剂后收缩压≥140 mmHg(糖尿病者≥135 mmHg)。
- 表观MRA难治性高血压定义为在上述治疗及MRA后收缩压≥140 mmHg(糖尿病者≥135 mmHg)。
主要发现
- 731例(15.2%)有表观难治性高血压,135例(2.8%)有表观MRA难治性高血压。
- 表观难治性高血压患者主要终点事件率为17.3(95%CI 15.6-19.1)/100人年,高于控制收缩压者的13.4(12.7-14.3)/100人年,调整率比1.28(95%CI 1.05-1.57)。
- 表观难治性高血压患者第4周和第16周收缩压降低,沙库巴曲缬沙坦组较缬沙坦组分别多降低-4.8(-7.0至-2.5)和-3.9(-6.6至-1.3)mmHg。
- 表观MRA难治性高血压患者第4周和第16周收缩压降低,沙库巴曲缬沙坦组较缬沙坦组分别多降低-8.8(-14.0至-3.5)和-6.3(-12.5至-0.1)mmHg。
- 第16周时表观难治性高血压患者收缩压达标比例:沙库巴曲缬沙坦组47.9% vs 缬沙坦组34.3%(调整OR 1.78,95%CI 1.30-2.43)。
关键数值与推荐
- 表观难治性高血压:使用缬沙坦、钙通道阻滞剂和利尿剂后收缩压≥140 mmHg(糖尿病者≥135 mmHg)。
- 表观MRA难治性高血压:在上述治疗及MRA后收缩压≥140 mmHg(糖尿病者≥135 mmHg)。
- 主要终点为心衰总住院和心血管死亡的复合终点。
临床怎么用
- 对HFpEF合并表观难治性高血压患者,可考虑使用沙库巴曲缬沙坦以改善血压控制。
- 即使患者已使用包括MRA在内的至少四类降压药,沙库巴曲缬沙坦仍可能有效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Patients with heart failure and preserved ejection fraction (HFpEF) frequently have difficult-to-control hypertension. We examined the effect of neprilysin inhibition on 'apparent resistant hypertension' in patients with HFpEF in the PARAGON-HF trial, which compared the effect of sacubitril-valsartan with valsartan. METHODS AND RESULTS: In this post hoc analysis, patients were categorized according to systolic blood pressure at the end of the valsartan run-in (n = 4795). 'Apparent resistant hypertension' was defined as systolic blood pressure ≥140 mmHg (≥135 mmHg if diabetes) despite treatment with valsartan, a calcium channel blocker, and a diuretic. 'Apparent mineralocorticoid receptor antagonist (MRA)-resistant' hypertension was defined as systolic blood pressure ≥140 mmHg (≥135 mmHg if diabetes) despite the above treatments and an MRA. The primary outcome in the PARAGON-HF trial was a composite of total hospitalizations for heart failure and death from cardiovascular causes. We examined clinical endpoints and the safety of sacubitril-valsartan according to the hypertension category. We also examined reductions in blood pressure from the end of valsartan run-in to Weeks 4 and 16 after randomization. Overall, 731 patients (15.2%) had apparent resistant hypertension and 135 (2.8%) had apparent MRA-resistant hypertension. The rate of the primary outcome was higher in patients with apparent resistant hypertension [17.3; 95% confidence interval (CI) 15.6-19.1 per 100 person-years] compared to those with a controlled systolic blood pressure (13.4; 12.7-14.3 per 100 person-years), with an adjusted rate ratio of 1.28 (95% CI 1.05-1.57). The reduction in systolic blood pressure at Weeks 4 and 16, respectively, was greater with sacubitril-valsartan vs. valsartan in patients with apparent resistant hypertension [-4.8 (-7.0 to -2.5) and 3.9 (-6.6 to -1.3) mmHg] and apparent MRA-resistant hypertension [-8.8 (-14.0 to -3.5) and -6.3 (-12.5 to -0.1) mmHg]. The proportion of patients with apparent resistant hypertension achieving a controlled systolic blood pressure by Week 16 was 47.9% in the sacubitril-valsartan group and 34.3% in the valsartan group [adjusted odds ratio (OR) 1.78, 95% CI 1.30-2.43]. In patients with apparent MRA-resistant hypertension, the respective proportions were 43.6% vs. 28.4% (adjusted OR 2.63, 95% CI 1.18-5.89). CONCLUSION: Sacubitril-valsartan may be useful in treating apparent resistant hypertension in patients with HFpEF, even in those who continue to have an elevated blood pressure despite treatment with at least four antihypertensive drug classes, including an MRA. CLINICAL TRIAL REGISTRATION: PARAGON-HF: ClinicalTrials.gov Identifier NCT01920711.
引用
- Jackson AM, Jhund PS, Anand IS, et al. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J. 2021. PMID: 34392331. doi:10.1093/eurheartj/ehab499
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。